To the Editor: With the recent publication by Iyer et al. [1] , it is very encouraging to see the considerable effort being made to develop non-endoscopic, noninvasive and cost-effective approaches for early diagnosis of Barrett's oesophagus, with potential applicability to primary care. In this new study, combined DNA hypermethylation of VAV3 and ZNF682 was used with an EsophaCap TM device for the detection of Barrett's oesophagus [1] . Previous studies investigated the potential of utilising nonendoscopic cell collection devices coupled with DNA methylation markers for Barrett's diagnosis [2, 3] , neither of which were cited [1] . Biomarkers identified by Chettouh et al.
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Utilising a two-step discovery process (n = 31 Barrett's; n = 7 controls), Chettouh et al. identified four candidates (TFPI2, TWIST1, ZNF345 and ZNF569) and validated them in non-endoscopic Cytosponge TM samples (n = 149 Barrett's; n = 129 controls) with matched TFF3 immunohistochemistry data [4] . These markers yielded AUC values of 78.7-87.7% which positively correlated with the length of the Barrett's segment; a combined marker analysis was not performed to avoid overfitting of the data.
Moinova et al. reported 412 differentially methylated regions (DMRs) in a discovery cohort (n = 14 Barrett's; n = 26 oesophageal adenocarcinoma (OAC); n = 26 controls).
Following their filtering process, CCNA1 was selected for validation in oesophageal brushings and non-endoscopic encapsulated balloon devices. VIM was then added to the validation phase following positive results in their previous studies. In balloon devices (n = 50 Barrett's; n = 36 controls), CCNA1 and VIM revealed specificities of 100% and 91.7% and sensitivities of 72% and 80%, respectively.
Iyer et al. identified 188 DMRs in a discovery cohort (n = 54 Barrett's; n = 18 controls), from which 25 were selected for validation along with other 35 OAC methylation markers reported in their previously published abstract [5, 6] . ELMO1 and CD1D were the top performers with AUC values of 0.94 and 0.93, respectively. A total of 19 methylation candidates were further validated in oesophageal brushings (16 OAC, 3 Barrett's) and EsophaCap TM samples (n = 19 Barrett's; n = 20 controls). VAV3 and ZNF682 were shown to be the best candidates for detecting Barrett's oesophagus through EsophaCap TM with a perfect area under the receiver-operating characteristic curve (AUC) of 1.0 (n = 19 Barrett's; n = 20 controls). The marker sensitivity was dependent on segment length (short versus long), although the cut-off was not provided. Interestingly, the reason for the selection of VAV3 is not apparent from the earlier publications or in the abstract cited by the authors to justify the choice [5, 6] and ZNF682 was not a discriminant biomarker in their oesophageal brushing cohort.
One drawback of non-endoscopic devices is the limited control over their passage through the distal oesophagus; if the devices fail to retrieve cells from the junction, biomarkers may not succeed in diagnosing Barrett's oesophagus. In the clinical trial BEST2 (n = 1,110), the Cytosponge-TFF3 test's overall sensitivity was 79.9% and increased to 87.2% with longer segments (≥3 cm) [4] and TFF3 false negatives were largely due to the lack of columnar cells in the specimen rather than failure of the TFF3 antibody. Exclusion of cases with < 5 columnar cell groups resulted in sensitivities of 91-98%, across five different centres [4] . Although Iyer et al. mention that TFF3 is expressed in normal gastric cells, it is only expressed in intestinal metaplasia [6] , a precursor to gastric carcinogenesis. These promising non-endoscopic approaches require testing in large-scale clinical trials to assess tolerability, sensitivity and specificity in the relevant population. BEST3 is an example of such trial with a cluster-randomised design (n = 13,000), currently mid-way through recruitment (www.best3trial.org).
